Background Hepatitis C elimination may be possible with broad uptake of direct-acting
antiviral treatments (DAAs). In 2016 the Australian government committed A $1.2 billion for …

A government‐funded interferon‐free direct‐acting antiviral (DAA) treatment programme for
chronic hepatitis C virus (HCV) infection has been available in Australia since March 2016 …

Combinations of direct‐acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the
majority of treatment‐naïve patients. Mass treatment programs to cure HCV in developing …

Australia was one of the first countries with unrestricted access to government subsidized
direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus. This study …

Objectives Novel treatments for hepatitis C demonstrate high cure rates, but current high
prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly …

OBJECTIVES: To quantify the burden of illness of chronic hepatitis C virus (HCV) infection
and estimate the impact of interferon-free direct-acting antiviral treatment on healthcare …

In the USA, over 3 million individuals are infected with the HCV and 75–85% of them have or
will develop chronic hepatitis C (CHC) which can lead to serious consequences such as …

State payers may face financial incentives to restrict use of high-cost medications. Yet,
restrictions on access to high-value medications may have deleterious effects on population …

The availability of curative, direct-acting antiviral drugs against hepatitis C virus (HCV)
sparks an ethical call for HCV eradication and provides essential tools to spearhead the …

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates
of 95% or more, represent a major clinical advance. However, the high list price of DAAs has …